Evotec SE

Evotec SE announced preliminary unaudited financial results for the first nine months of 2026, which exceeded market expectations. The company reported Group revenues of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million for the period. Evotec also reaffirmed its full-year 2026 guidance for Group revenues and adjusted Group EBITDA. Full financial results for the third quarter and nine months of 2026 are scheduled for release on November 5, 2026.

Evotec SE announced its second quarter and first half 2026 results, reporting a 19.2% decrease in H1 Group revenues to €300.1 million and an Adjusted Group EBITDA loss of €42.7 million. The company updated its full-year 2026 outlook, lowering revenue expectations to €570-610 million and Adjusted Group EBITDA to a loss of €70-105 million, primarily due to shifts in partnership timing and lower revenue conversion. Despite challenging market conditions and significant net losses, Evotec highlighted growing commercial momentum in D&PD and Just – Evotec Biologics, and confirmed that its 'Horizon' transformation initiative is on track to deliver cost savings.

Evotec SE announced preliminary unaudited financial results for H1 2026, reporting Group revenues of approximately €300.1 million and adjusted Group EBITDA of -€42.7 million. The company significantly updated its full-year 2026 outlook, now expecting Group revenues of €570-610 million and adjusted Group EBITDA of -€70 to -105 million, down from previous guidance. This revision is primarily attributed to timing delays in existing and new strategic partnerships, with some revenues shifting to 2027. Despite the lowered outlook, Evotec noted positive base business momentum, including a 28% year-on-year increase in D&PD net sales.

The Goldman Sachs Group, Inc. has notified an increase in its total voting rights in Evotec SE to 14.62% as of June 23, 2026. This represents an increase from the previously notified 12.42%. The new holding comprises 0.16% voting rights attached to shares and 14.46% through various financial instruments, including rights to recall, rights of use, convertible bonds, swaps, and call warrants.

Evotec SE filed a Form 6-K reporting a directors' dealing by Dr. Cord Dohrmann. Dr. Dohrmann, a member of the managing body, sold Evotec SE shares on June 15, 2026, at a price of 4.81 EUR per share, with the total transaction value reaching 576,720.00 EUR. The filing was made on June 16, 2026.

Evotec SE reported a challenging first quarter for 2026, with group revenues declining 22% to €156.6 million and adjusted Group EBITDA turning negative at €(21.9) million, primarily due to a strong prior-year comparison and market softness. Despite the financial downturn, the company confirmed its full-year 2026 guidance and is actively implementing its 'Horizon' strategic transformation, incurring €75.0 million in reorganization costs. Evotec also announced key leadership appointments, expects significant proceeds from an investment exit, and initiated a strategic review of its portfolio and capital structure.

Evotec SE announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of its Supervisory Board at the upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman and a proposal to increase the Supervisory Board from six to seven members. Additionally, Evotec has entered into a cooperation agreement with key shareholder MAK Capital Fund LP, following constructive discussions, which includes customary voting and cooperation commitments.